30 Other Trials 1 1 0 8 8 1274 http://clinicaltrials.dfhcc.harvard.edu/trials/1274 Safety, Tolerability and Systemic Absorption of Menadione Topical Lotion for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash This is a clinical research study of an experimental new medication, Menadione Topical Lotion (MTL). The study lotion is experimental and has not been approved for public use. Hana Biosciences, Inc., the company that is developing MTL, is the sponsor of this study. EGFR inhibitors are used to treat non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer, breast cancer and head and neck cancer. One of the side effects of EFGR inhibitors is skin toxicites including an acneform skin rash. This study is a Phase 1 study. The main purposes of this study are: - Evaluate the safety and tolerability of Menadione Topical Lotion as an emergent and pre-emergent treatment for EGFR inhibitor-associated rash - Evaluate the systemic absorption and bioavailability of Menadione Topical Lotion as an emergent and pre-emergent treatment for EGFR inhibitor-associated rash It is planned that up to 24 patients undergoing EGFR inhibitor therapy will take part in this study at multiple clinical centers. Recruiting 30 Other Trials http://clinicaltrials.dfhcc.harvard.edu/diagnoses/30-other-trials Phase 1 1319 http://clinicaltrials.dfhcc.harvard.edu/trials/1319 Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy RATIONALE: Sunitinib malate may stop the growth of cancer cells by blocking blood flow to the cancer and by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects of sunitinib malate in treating HIV-positive patients with cancer undergoing highly active antiretroviral therapy. Recruiting 30 Other Trials http://clinicaltrials.dfhcc.harvard.edu/diagnoses/30-other-trials Phase 1 1182 http://clinicaltrials.dfhcc.harvard.edu/trials/1182 Fludarabine-based Conditioning for Severe Aplastic Anemia The purpose of this study is to continue to optimize conditioning regimens in high-risk patients with severe aplastic anemia (SAA) transplanted with marrow from human leukocyte antigen (HLA)-compatible unrelated donors. Specifically, the study will address whether the addition of fludarabine to the conditioning regimen of Deeg et al. will permit reduction in the cyclophosphamide (CY) dose to a point where survival is maintained or improved and sustained hematopoietic engraftment is maintained or improved with reduced major regimen-related toxicity (RRT) and/or early death. Recruiting 30 Other Trials http://clinicaltrials.dfhcc.harvard.edu/diagnoses/30-other-trials 20 Pediatric Blood Related http://clinicaltrials.dfhcc.harvard.edu/diagnoses/20-pediatric-blood-related 1189 http://clinicaltrials.dfhcc.harvard.edu/trials/1189 Effectiveness of Etanercept for Idiopathic Pneumonia Syndrome Following Stem Cell Transplantation The study is designed as a Phase III, multi-center randomized, double-blind, placebo-controlled trial investigating the use of etanercept for the treatment of acute, non-infectious pulmonary dysfunction (IPS) occurring after allogeneic hematopoietic cell transplantation (HCT). Recruiting 30 Other Trials http://clinicaltrials.dfhcc.harvard.edu/diagnoses/30-other-trials 1218 http://clinicaltrials.dfhcc.harvard.edu/trials/1218 Kogenate Liplong Study - BAY 79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A A study to assess treatment with a new formulation of recombinant factor VIII reconstituted with liposomes (Bay 79-4980) to evaluate whether a once-a-week treatment is safe and can prevent bleeds in subjects with severe haemophilia A. Recruiting 30 Other Trials http://clinicaltrials.dfhcc.harvard.edu/diagnoses/30-other-trials 1239 http://clinicaltrials.dfhcc.harvard.edu/trials/1239 Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult Subjects Compared to That of Episodic Treatment. (SPINART) To evaluate the effect of secondary prophylaxis on bleeding frequency (number of bleeds per year) and on joint damage compared to episodic treatment. Recruiting 30 Other Trials http://clinicaltrials.dfhcc.harvard.edu/diagnoses/30-other-trials 1267 http://clinicaltrials.dfhcc.harvard.edu/trials/1267 Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To 11 Years Old Who Are At High Risk For Systemic Fungal Infection In this study we will measure the concentration of the drug called voriconazole which is used to fight infections caused by fungus in children who usually are cancer patients and have their immune system down. Since we know the dose in adults, and we think we know the matching doses in the young patients ages 2 to 12 years old, we will compare the amount of drug that goes into the system with what we know works in adults. We give the drug by a needle directly into the blood, then few days later we stop that and give the drug by mouth. Meanwhile, we draw a little bit of blood at certain times to measure the drug in it. Recruiting 30 Other Trials http://clinicaltrials.dfhcc.harvard.edu/diagnoses/30-other-trials 1438 http://clinicaltrials.dfhcc.harvard.edu/trials/1438 Expanded Access Trial of Plant Expressed Recombinant Glucocerebrosidase (prGCD) in Patients With Gaucher Disease This is an open-label expanded access trial of prGCD in patients with Gaucher disease who require enzyme replacement therapy (ERT) and who have been treated with imiglucerase but for whom the dose has been reduced or discontinued due to shortage of the product. Recruiting 30 Other Trials http://clinicaltrials.dfhcc.harvard.edu/diagnoses/30-other-trials